A.J. Minter reinstated by Mets after lat strain ended his 2024 season early

What happened

The Mets announced the reinstatement of left-handed reliever A.J. Minter from the 60-day injured list, closing out a lengthy absence that traces back to a lat strain that cut his 2024 campaign short. The club paired that move with two others on the addition side: infielder/outfielder Jared Young was reinstated from the 10-day injured list, and infielder Eric Wagaman was selected to the active roster. Tim Britton and Will Sammon of The Athletic reported most of the moves before the official club announcement came through.

To create room on the active roster, the Mets placed outfielder Tyrone Taylor on the 10-day injured list with a right hip flexor strain, and optioned right-hander Jonathan Pintaro and outfielder Nick Morabito.

The 40-man side of the ledger required its own arithmetic. The Mets entered the day with one vacancy on their 40-man roster — enough to absorb either Minter or Wagaman, but not both. Per the club's announcement, a corresponding move to open a second spot would be disclosed prior to game time, meaning the full shape of the shuffle was not yet visible when the transactions were made public.

Why it matters

Minter and the Mets agreed to a two-year, $22 million deal heading into the 2025 season. By any measure, the return on that investment has been limited so far. He logged 11 innings in 2024 before the lat strain intervened, ultimately requiring treatment that ended his season. A 60-day IL stint removes a player from the 40-man count entirely — a designation that signals the club did not expect a quick turnaround — so his reinstatement represents the completion of what was, by design, a long road back.

Left-handed relievers with established track records carry real operational value in a bullpen, and the Mets are now getting one back, per the club's announcement. Whether Minter slots immediately into high-leverage situations or works his way back into the staff's rhythm is the kind of question the next few appearances will answer — but that answer belongs to the future, not this desk.

The Taylor development adds a layer of complexity to the outfield picture. His placement on the 10-day IL with a right hip flexor strain is the kind of move that can look routine on a transaction wire and feel less routine when a roster is already in motion. Morabito's option and the Taylor IL placement are, in effect, the mechanism that clears the active roster path for the returning players.

Why is there still a 40-man move pending?

Under general league roster mechanics, the 60-day IL removes a player from the 40-man count while he is on it — so Minter's reinstatement consumes a 40-man spot that his IL placement had been, in a sense, holding open for him. Wagaman's selection to the roster is a separate addition that requires its own vacancy. The Mets had one open spot, which covered one of those two needs. The second spot, per the club's announcement, was still being arranged when the transaction wave was made public, with a resolution expected before first pitch.

That is not unusual when a club is managing multiple moves simultaneously, but it does mean the full accounting of this roster shuffle was incomplete at the time of the announcement. Whatever form the pending move takes — and the announcement does not specify — it will determine who absorbs the roster cost of adding Wagaman alongside Minter.

What we don't know yet

The most immediate open question is that second 40-man move. A designation for assignment, a release, or a transfer to the 60-day IL would each carry different implications for the players involved, and none of those possibilities is named in the announcement.

Beyond the paperwork, Minter's workload management coming off a lat strain and a 60-day IL stint is genuinely uncertain. The announcement does not specify a role, a usage plan, or any deployment timeline. Eleven innings in 2024 is a thin recent sample, and how the Mets intend to sequence him back into a live bullpen is not addressed.

Taylor's timeline is similarly open. A 10-day IL placement establishes a minimum absence, but right hip flexor strains carry a range of outcomes, and the announcement does not offer a prognosis or an expected return window beyond the placement itself.

Young's reinstatement from the 10-day IL also arrives without a stated timeline for how he fits into the club's plans. He returns as an infielder/outfielder, which gives the Mets positional flexibility, but the specifics of his role going forward are not addressed in the announcement.

What to watch

The pending 40-man move is the most time-sensitive item on the list. It was due before game time per the club's own framing, so it should resolve quickly — and whatever form it takes will tell you something about how the Mets are currently managing their roster depth.

Minter's first appearances back will draw attention for obvious reasons. A reliever returning from a lat strain that required treatment ending his 2024 season is not a player anyone should assume is simply picking up where he left off. The Mets' bullpen usage in the days ahead — who pitches in which spots, and how Minter is sequenced — will be the practical signal of how much the club trusts what they have seen from him in his recovery.

The Taylor situation is the quieter watch item. Hip flexor strains in outfielders can linger, and the 10-day IL is a floor, not a ceiling. If his absence extends, the outfield depth that Morabito and Young represent becomes more than a roster footnote — and the options the Mets exercised in this announcement may end up looking less like housekeeping and more like load-bearing structure.

The two-year, $22 million commitment to Minter is the financial backdrop against which his return gets evaluated. Per the club's announcement, the Mets have not been able to extract meaningful value from that deal yet. His reinstatement is the first real opportunity to change that accounting — though how much he pitches, and how effectively, remains entirely ahead of us.